37 filings
8-K
NAMS
NewAmsterdam Pharma Company NV
11 Jun 24
NewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United
8:12am
8-K
NAMS
NewAmsterdam Pharma Company NV
7 Jun 24
Submission of Matters to a Vote of Security Holders
4:15pm
8-K
NAMS
NewAmsterdam Pharma Company NV
9 May 24
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
8:00am
8-K
NAMS
NewAmsterdam Pharma Company NV
1 Apr 24
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
8:16am
8-K
NAMS
NewAmsterdam Pharma Company NV
4 Mar 24
Regulation FD Disclosure
8:06am
8-K
ox5b8oe7movi ru84mp
28 Feb 24
NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update
8:11am
8-K
alst246sapi5l
15 Feb 24
NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
4:18pm
8-K
rnznwcxpv km1zc9gc28
22 Jan 24
Regulation FD Disclosure
8:01am
8-K
qrpr60xrrt 7c2
8 Jan 24
NewAmsterdam Pharma Appoints William H. Lewis, J.D., M.B.A. as Chair of its Board of Directors
8:21am
8-K
0m80i7pyj6oivhfr
4 Jan 24
NewAmsterdam Pharma Announces 2024 Strategic Priorities
8:08am
6-K
8fuf ubwz
13 Nov 23
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights
12:00am
6-K
0uqb6766is2aqo46gi
23 Oct 23
NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial Officer
8:12am
6-K
qii9s62n2py1zbt 7x
25 Sep 23
Current report (foreign)
8:10am
6-K
70bsl0iu sc1b
21 Sep 23
NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients
7:14am
6-K
9bxn7o
28 Aug 23
Current report (foreign)
4:16pm
6-K
ioouixtbz5uz8
14 Aug 23
NewAmsterdam Pharma Announces Appointment of William “BJ” Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial Officer
4:52pm
6-K
gvgbw
7 Aug 23
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial Highlights
7:38am
6-K
9xbyu
7 Aug 23
Research and development expenses
7:24am
6-K
o4l66 jgnhjxp
26 Jul 23
NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROADWAY Clinical Trial Evaluating
8:00am
6-K
wcsch
21 Jun 23
Current report (foreign)
4:01pm